Bioheart Inc.

Discovery, development and commercialization of cell-based therapy products for the treatment of cardiovascular diseases, including myocardial infarction, congestive heart failure and cardiovascular electrical abnormalities.

Bioheart is a privately held company with headquarters in Ft. Lauderdale, Florida.

Howard J. Leonhardt, CEO
Richard T. Spencer, JD, MBA,VP-Clinical Affairs and Physician Relations
Kristin Comella, M.S. - Director, Cell Process Development and R&D
Scott R. Bromley - Vice President of Marketing and Private Finance
Sergio Pinski - M.D. Medical Director.

Howard J. Leonhardt, Chairman
Samuel S. Ahn, MD
Bruce C. Carson
William P. Murphy, Dr.
Richard Spencer
Carlos de Céspedes
Eric N. Falkenberg
David Gury
Sami Hamade
Linda Tufts

Sam Ahn, M.D.
Edward Diethrich, M.D.
George J. Magovern, M.D.
Nicholas S. Peters, M.D., Ph.D
Barry T. Katzen, M.D.
Nicolas Chronos, M.D.
Stephen G. Ellis, M.D.
Tim Henry, M.D.
Richard Heuser, M.D.
Zvonimir Krajcer, M.D.
Martin B. Leon, M.D.
James Margolis, M.D.
Stephen Ramee, M.D.
Kumar Ravi, M.D.
Warren Sherman, M.D.
Lawrence Solomon, M.D.
Juan C. Chachques, M.D., Ph.D.
Ray Chiu, M.D., Ph.D.
Eric Crumpler, Ph.D.
Miranda Grounds, Ph.D.
Wendell King
Keith March, M.D., Ph.D.
Felipe Prósper, Ph.D.
Syde A. Taheri, M.D.
Stuart Williams, Ph.D.
Richard Ham, PhD.
Race L. Kao, Ph.D.
Camillo Ricordi
Doris Taylor, Ph.D.

13794 NW 4th Street, Suite 212
Sunrise, FL 33325
USA
Phone: +1-954-835-1500
Fax: +1-954-845-9976

Bioheart’s autologous cell transplantation technology (MyoCell™) is delivered to the patient either percutaneously or surgically. The therapy is designed to regenerate infarcted, scarred or non-functioning myocardial tissue into functioning muscle. The second lead product of the company is MyoCath - SR 200, a percutaneous needle injection catheter for delivering cell therapy or other compounds to the myocardial tissue. The third product is a cell-based product for the treatment of ventricular tachycardia (VT; MyoCell VT), and the forth, a cell-based product used for the treatment of sinoatrial nodal dysfunction disease (BioPace); i.e. a biological pacemaker.

MyoCell is currently in clinical trials in the US and Europe (Phase I/II); MyoCath-SR200 is currently in clinical trials in Europe (Phase I/II)

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.